EMA qualifies first artificial intelligence tool to diagnose inflammatory liver disease (MASH) in biopsy samples | European Medicines Agency (EMA)

EMA’s human medicines committee (CHMP) has issued the first Qualification Opinion (QO) on an innovative development methodology based on artificial intelligence (AI). The tool, called AIM-NASH, helps pathologists analyse liver biopsy scans to identify the severity of MASH (metabolic dysfunction associated steatohepatitis; formerly known as non-alcoholic steatohepatitis NASH) in clinical trials.

MASH is a condition where fat builds up in the liver, causing inflammation, irritation and…